Market news

SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SOPHiA GENETICS is back in focus as analysts reset their central price views, with fair value moving from US$9.00 to US$9.75. Recent research linking the company’s role in data driven oncology and rare disease diagnostics with Q2 results and higher guidance has supported price targets in a US$9 to US$12 range, while still flagging execution and valuation risk. Read on to see how these shifting targets feed into the broader SOPHiA GENETICS story and how you can track the narrative from...

Detailed price information for Sophia Genetics Sa (SOPH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Sophia Genetics Sa (SOPH-Q) from The Globe and Mail including charting and trades.

SOPHiA GENETICS is tasked with developing its Solid Tumor application as a decentralised companion diagnostic.

Sophia Genetics SA (SOPH) delivers 27% revenue growth, raises full-year guidance, and announces landmark AstraZeneca CDX deals and MSK joint venture.

Sophia Genetics announced a partnership with AstraZeneca to develop two cancer diagnostic tests and also raised its full-year revenue forecast.

AstraZeneca (AZN) has entered into a multi-year global collaboration with Sophia Genetics (SOPH) aim

SOPHiA GENETICS (NASDAQ:SOPH) reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements. Revenue for the second quarter totaled $23.3 millio

SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).

BOSTON and ROLLE, Switzerland , July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets...